

To: Dr. Wang Fengwei, Professor of medicine

From: Taixiang WU, Secretary General, Chinese Ethics Committee of Registering Clinical Trials

Email: chictr@vip.qq.com

Date: July 19, 2017

Application for ethical review for clinical study involving human subjects

I write to inform you that approval has been given to your application for human subjects ethics review of the following project for a period from July 20, 2017 to July 19, 2020.

Project title: A phase II study on the effect of Gemcitabine combined with Nedaplatin (GP regimen) concurrent radiotherapy for recurrent or locally metastatic head and neck squamous cell carcinoma

Institute: Tianjin People's Hospital

Principal investigator: Dr. Wang Fengwei, Professor of medicine

Expected start date of project: July 20, 2017

Reference number: ChiECRCT20170178

You will be held responsible for the ethical approval granted for the project and the ethical conduct of the personnel involved in the project.

You are responsible for informing the Chinese Ethics Committee of Registering Clinical Trials in advance of any changes in the proposal or procedures which may affect the validity of this ethical approval.

Taixiang WU, Professor

Secretary General,

Chinese Ethics Committee of Registering Clinical Trials

